To test the hypothesis that preconditioning animals with amifostine improves ventilator-induced lung injury via induction of antioxidant defense enzymes. Mechanical ventilation at high tidal volume induces reactive oxygen species production and oxidative stress in the lung, which plays a major role in the pathogenesis of ventilator-induced lung injury. Amifostine attenuates oxidative stress and improves lipopolysaccharide-induced lung injury by acting as a direct scavenger of reactive oxygen and nitrogen species. This study tested effects of chronic amifostine administration on parameters of oxidative stress, lung barrier function, and inflammation associated with ventilator-induced lung injury.
A cute lung injury (ALI) is a devastating clinical syndrome characterized by severe lung inflammation and vascular barrier disruption that affects Ͼ200,000 patients per year in the United States and is associated with a mortality rate of 30%-50% (1, 2) . Mechanical ventilation remains an imperative treatment for ALI, especially for the patients with acute respiratory distress syndrome. However, mechanical ventilation, particularly with high tidal volume (HTV), can worsen or even cause de novo lung injury (3) (4) (5) (6) (7) (8) . Despite recent advances in low tidal volume ventilator strategies and a better understanding of the underlying inflammatory pathophysiology of ALI, there remain few effective treatments for this devastating illness. Redox imbalance and lung oxidative damage contributes to various pathologic conditions including sep-tic inflammation and ventilator-induced lung injury (VILI). Exacerbation of preexisting lung injury by excessive mechanical ventilation worsens lung damage and increases associated oxidative stress, which remains a serious concern in defining optimal ventilation strategies. This study examined the role of amifostine preconditioning in the attenuation of oxidative damage in a simplified model of lung injury induced by HTV mechanical ventilation alone.
Reactive oxygen species (ROS) and reactive nitrogen species are important factors that exacerbate various pathologic conditions, such as acute respiratory distress syndrome, sepsis, and ALI (9, 10) . Excessive mechanical stretch of lung tissue associated with HTV mechanical ventilation induces intracellular oxidative stress by several mechanisms, including induction of mitochondrial systems (11) , activation of NADPH oxidase (12) , or xanthine oxidoreductase (13) . In vitro, cyclic stretch (CS) triggers ROS production in lung epithelial and endothelial cells (ECs) as early as 30 mins after exposure (11, 14 -16) , suggesting that ROS induced by mechanical ventilation is an early event in the pathogenesis of VILI (10, 17) . Consistent with this in vitro evidence, a redox imbalance has been observed in lungs exposed to mechanical ventilation (18) . Lung cells counteract the oxidative stress induced by various stimuli by using a variety of antioxidant defense mechanisms. Manganese superoxide dismutase (SOD2) and catalase are effective endogenous antioxidant enzymes. SOD2, an inducible antioxidant enzyme located in the mitochondria, converts superoxide anion into hydrogen peroxide, followed by the subsequent conversion of hydrogen peroxide into H 2 O by catalase. The pathologic role of superoxide anion and high hydrogen peroxide levels has been welldocumented. Impairment of SOD2 has been related to asthma pathophysiology (19) , decreased pulmonary radiation resistance (20) , and increased sensitivity to oxygen toxicity (21) . Likewise, catalase also plays an important role in lung diseases. Mitochondrial localization of catalase attenuates H 2 O 2 -induced lung epithelial cell death (22) , and targeting of catalase to the endothelium, using catalase conjugated to an angiotensinconverting enzyme antibody, attenuates ischemia-reperfusion injury of the lung in vivo (23) . Thus, therapeutic strategies aimed at the upregulation of antioxidant defense enzymes may be beneficial for the treatment of pathologic conditions associated with oxidative stress including VILI.
Amifostine (S-2[3-aminopropylamino]ethylphosphorothioic acid, WR-2721) is a phosphorothioate that is converted to its active free thiol form through dephosphorylation by alkaline phosphatase in tissue (24) . It is currently the only radioprotective drug approved by the US Food and Drug Administration for use as a cytoprotective agent to decrease the incidence of moderate-to-severe xerostomia in patients undergoing postoperative radiation therapy for the treatment of head and neck cancer (25) . Our previous study demonstrated the protective effect of a single amifostine administration in lipopolysaccharide-induced ALI through a direct free radical scavenging effect (26) . In addition to the immediate amifostine antioxidant effects attributable to free oxygen radical scavenging, amifostine exhibits additional activities. For example, daily administration of amifostine for 3 days caused a 20%-40% increase in cellular radiation resistance in animals exposed to ionizing radiation (27) . Another study shows improvement of hemodynamic parameters in rat models of doxorubicin-induced cardiotoxicity, in which amifostine was chronically administered at doses up to 75 mg/kg (28) .
In this study we investigated the effect of daily administration of amifostine during 3 consecutive days before mechanical ventilation on the development of VILI and examined stress-induced pathways, levels of SOD2 and catalase expression, and enzymatic activity as potential molecular mechanisms underlying the protective effects of chronic amifostine preconditioning.
MATERIALS AND METHODS
An expanded Materials and Methods section is available in the online data supple-ment (Supplemental Digital Content 1 http://links.lww.com/CCM/A285).
Reagents and Cell Culture. Human pulmonary artery ECs were obtained from Clonetics (Walkersville, MD). Unless otherwise specified, all reagents were obtained from Sigma (St. Louis, MO).
In Vivo Model of VILI. All animal care and treatment procedures were approved by the University of Chicago Institutional Animal Care and Use Committee and were handled according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The ventilation protocol was performed as previously described (29 -31) . Ventilation was performed at tidal volume of 30 mL/kg, 75 breaths per minute, and 0 positive end-expiratory pressure for 4 hrs. Nonventilated animals were used as controls. Amifostine or vehicle was administered by intraperitoneal injections daily for 3 days, and on day 4 the mice were anesthetized and exposed to mechanical ventilation. At the end of ventilation experiments, bronchoalveolar lavage (BAL) was performed, and lung injury was assessed by BAL total cell count and protein content measure- ments (6, 26, 32) . Measurement of Evans blue accumulation in the lung tissue has been described previously (30, 33, 34) and outlined in the supplemental data (Supplemental Digital Content 1, http://links.lww.com/CCM/A285). The histologic assessment of lung injury by microscopy was further performed by visual analysis of paraffin-embedded lung sections stained with hematoxylin and eosin.
Measurements of SOD and Catalase Enzymatic Activity, Malone Dialdehyde Content, and Detection of Oxidized Proteins. Measurements in homogenized lung tissue or cell lysates were performed using commercial kits according to the manufactures' protocols.
Cell Culture Under CS. All CS experiments were performed using an FX-4000T Flexcell Tension Plus system (Flexcell International, Hillsborough, NC) according to the previously established protocol (35, 36) . EC were treated daily with 0.5 mmol/L or 1 mmol/L amifostine for 3 days. Medium was changed every day with fresh amifostine. Preconditioned cells were exposed to 18% CS for 2 hrs. Thrombin (0.1 U/mL) was added 15 mins before termination of CS. At the end of experiment, cell lysates were collected for Western blot analysis or cells were used for live ROS detection using Image-iT LIVE Green Reactive Oxygen Species Detection Kit (Molecular Probes, Eugene, OR) as described elsewhere (26) .
Statistical Analysis. Results are expressed as means Ϯ SD of three to ten independent experiments. Multiple group comparisons of control and experimental groups subjected to HTV and treated with various doses of amifostine (BAL cell count and protein content, lung tissue malone dialdehyde (MDA) content, analysis of cell and lung tissue catalase and SOD activities, H2DCFDA assay of ROS production in cell cultures) were performed using one-way analysis of variance and Tukey post hoc multiple comparison test; p Ͻ .05 was considered statistically significant.
RESULTS
Preconditioning With Amifostine Attenuates VILI and Lung Vascular Permeability. HTV significantly elevated BAL inflammatory cell counts. This effect was markedly attenuated by 3-day amifostine pretreatment at 25 mg/kg, 50 mg/kg, and 100 mg/kg (42%, 33%, and 25%, respectively) ( Fig. 1A) , whereas amifostine treatment at 10 mg/kg was not effective. Likewise, HTV caused significant barrier disruption, inducing an increase in BAL protein compared with vehicle control. This effect was significantly attenuated by triple daily amifostine treatment at 25 mg/kg and 50 mg/kg, but not at 10 mg/mL and 100 mg/mL doses (Fig. 1B) . The protective effects of amifostine against vascular leak were further assessed by measurement of Evans blue leakage into the lung tissue. The amifostine dose causing the maximal protective effect (25 mg/kg) was used in these experiments. HTV induced noticeable Evans blue leakage from the vascular space into the lung parenchyma, which was significantly decreased by amifostine pretreatment ( Fig. 2A) . These results were confirmed by quantitative analysis of Evans blue-labeled albumin accumulation in the lung tissue sample (Fig. 2B ). Histologic analysis of lung sections revealed lung recruitment of inflammatory cells and areas of alveolar hemorrhage indicative of vascular disruption with HTV ventilation (control, 5.9 Ϯ 1.7 cells/field; amifostine alone, 5.7 Ϯ 1.6 cells/field vs. 48.8 Ϯ 9.0 cells/field for HTV; p Ͻ .01). These effects were attenuated by amifostine (14.2 Ϯ 2.9 cells/field; p Ͻ .01 vs. HTV) ( Fig. 2B ). These results strongly suggest that amifostine preconditioning has a protective effect for HTV-induced lung injury.
Amifostine Attenuates Oxidative Stress Induced by HTV. HTV increased lung tissue MDA content, and this increase was attenuated by amifostine ( Fig.  3A ). HTV also enhanced nitrotyrosine accumulation in the lung tissue, which was attenuated by amifostine pretreatment (Fig. 3B ). Similar results were obtained by analysis of oxidized proteins. Western blot analysis of lung tissue homogenates Chronic amifostine preconditioning alleviates lung vascular permeability and cellular infiltration induced by high tidal volume (HTV) mechanical ventilation. Mice were pretreated with vehicle or amifostine (25 mg/kg) for 3 days, followed by ventilation at HTV. Control animals were treated with vehicle (phosphate-buffered saline) or amifostine alone. A, Lung vascular permeability was assessed by Evans blue accumulation in the lungs. The panels show right and left lungs, respectively, which were excised after perfusion to remove blood and imaged. Bar graph depicts quantitative spectrophotomertic analysis of Evans blue-labeled albumin content in the lung tissues. Data are presented as mean Ϯ SD; n ϭ 4 -6 mice per group; ***p Ͻ .001. B, Lung specimen from control and experimental animals were stained with hematoxylin and eosin. Images are representative of 4 -6 lung specimen for each condition; ϫ40 magnification. demonstrated that HTV induced a significant increase in oxidized proteins compared to vehicle control animals, which was attenuated by 25 mg/kg amifostine treatment ( Fig. 3C ). These data together show that three parameters reflecting oxidative stress in ventilated lungs are suppressed by amifostine.
Amifostine Attenuates HTV-Induced Oxidative-Sensitive Signaling Pathways. HTV increased p38, JNK, and Erk1/2 phosphorylation as determined by Western blot analysis of lung tissue samples with corresponding phospho-specific antibodies. Amifostine pretreatment significantly attenuated HTV-induced phosphorylation of p38 and JNK MAP kinases but did not affect Erk1/2 (Fig. 4) .
The significant Evans blue accumulation in lung tissue caused by HTV as described suggests impaired lung vascular barrier function. Therefore, we next analyzed the effects of HTV and amifostine treatment on the activation of cytoskeletal proteins regulating vascular permeability. Our data demonstrate that HTV induced myosin protein phosphatase phosphorylation at Thr850 and myosin light chain phosphorylation in lungs, and that these signaling events were markedly suppressed by amifostine treatment (Fig. 4 ). HTV induced a marked degradation of IB, which was blocked by amifostine preconditioning ( Fig. 4) .
Effects of Amifostine on SOD2 and Catalase Enzymatic Activity. Chronic preconditioning of mice with amifostine in the range of 50 -100 mg/kg increased SOD2 enzymatic activity in the homogenized lung tissue samples ( Fig. 5A) , whereas short-term treatment with amifostine (100 mg/kg; 30 mins) had no effect on SOD2 activity (data not shown). HTV had no effect on basal SOD2 activity in the lungs of untreated mice (Fig. 5A) .
Analysis of catalase activity showed that in contrast to the effects on induction of SOD2, amifostine preconditioning did not increase catalase activity in nonventilated mice (Fig. 5B ). Interestingly, exposure to HTV decreased catalase activity in the lungs of vehicle-treated mice. Despite apparently elevated levels of catalase activity in (HTV ϩ amifostine) group, the difference between this and HTV groups was not statistically significant (p ϭ .54). Of note, catalase activity in (HTV ϩ amifostine) group corresponded to amifostine-treated nonventilated mice. Western blot analysis showed a significant increase in SOD2 protein content in the lungs of amifostine-preconditioned mice, whereas catalase protein levels remained unchanged (Fig. 5C ).
The SOD inhibitor DECT blocks suppression of HTV-induced inflammatory cell and protein accumulation in BAL samples from mice preconditioned with amifostine. The role of SOD activity for amifostine's protective effects against VILI was further tested in experiments with the pharmacologic SOD inhibitor DECT. DECT blocked completely the amifostine preconditioning caused reduction of HTV-induced inflammatory cell and protein accumulation in BAL samples (Fig. 6A) . Abrogation of the amifostine-induced lung-protective ef- fects by DECT was also associated with the re-emergence of p38 MAP kinase activation and degradation of the nuclear factor-kappa B (NF-B) subunit IB␣ (Fig. 6B) .
Amifostine inhibits ROS production and inflammatory signaling by pulmonary ECs in the in vitro two-hit model of VILI. We have previously described an in vitro two-hit model of VILI (37, 38) to directly test the effect of pathologically relevant CS (18% CS) and barrierdisruptive agonists on ROS production in pulmonary ECs. Thrombin alone caused a slight but significant increase in ROS production, whereas 18% CS induced a more robust ROS production. The combination of 18% CS and thrombin induced the largest increase in ROS ( Fig.  7A and B) . Endothelial cell preconditioning with amifostine before CS and thrombin stimulation dramatically inhibited ROS generation in response to combined CS and thrombin. Because amifostine was not present in the medium during the combined CS and thrombin challenge, these data exclude the effects of amifostine as a direct ROS scavenger and strongly suggest an additional mechanism of action.
Amifostine Enhances SOD2 Activity in Human Pulmonary Artery ECs. Chronic human pulmonary artery ECs preconditioning with 0.5 mmol/L and 1.0 mmol/L amifostine enhanced SOD2 activity in both control cells and cells exposed to pathologic CS and thrombin ( Fig. 8 ). Thrombin alone had no effect on SOD2 activity as compared to vehicle control. CS caused a decrease in SOD2 activity compared with vehicle control cells; however, the mean value did not reach significance (n ϭ 3; p ϭ .055).
Involvement of Oxidative Stress-Sensitive Signaling Pathways in
Response to CS and HTV. Similar to our in vivo results (Fig. 4 ), EC stimulation with 18% CS and thrombin increased phosphorylation of p38, JNK, and Erk1/2 MAP kinases, increased phosphorylation of myosin protein phosphatase, myosin light chain, and the p38 cytoskeletal target HSP-27, and also caused degradation of IB␣ (Fig. 9A ). The combination of 18% CS and thrombin addition exhibited synergistic effects on the phosphorylation of p38, JNK, myosin protein phosphatase, and myosin light chain, whereas pretreatment with amifostine markedly attenuated these signaling events. Unlike p38 and JNK MAP kinases, amifostine did not attenuate phosphorylation of Erk1/2 in-duced by thrombin, CS, or their combination. In agreement with the effects observed in vivo, chronic preconditioning of human pulmonary EC cultures with amifostine significantly increased SOD2 protein expression ( Fig. 9B ).
DISCUSSION
Pathologic mechanical stress associated with mechanical ventilation at HTV leads to elevated ROS production by lung cells, and the impact of oxidative stress in the pathogenesis of VILI has become well-recognized (39) . Excessive activation of redox-sensitive signaling leads to further vascular barrier dysfunction culminating in pulmonary edema and ALI (40, 41) . However, therapeutic approaches to enhance antioxidant defense mechanisms in ALI/acute respiratory distress syndrome patients have yet to be developed.
This study shows for the first time to our knowledge that chronic amifostine preconditioning attenuates ventilatorinduced lung injury and suppresses associated inflammatory and barrier disruptive signaling pathways. The major Figure 7 . Amifostine (Amif) inhibits cyclic stretch (CS)-induced and thrombin (Thr)-induced reactive oxygen species production in human pulmonary endothelial cells. Control and amifostinepreconditioned human pulmonary artery endothelial cells grown on BioFlex plates were exposed to 18% CS followed by Thr stimulation or left under static conditions. To detect reactive oxygen species, 30 mins before termination of the experiment cells were incubated with fluorescent dye for reactive oxygen species, dichlorodihydrofluorescein (10 mol/L), under continuing CS stimulation. A, Cells were imaged using inverted fluorescent microscope. B, Fluorescence intensity determined in vehicle control cells was taken as 100%. Results of six images from the entire cell monolayer were averaged and have been reproduced in three independent experiments. Results are presented as mean Ϯ SD; ***p Ͻ .001.
finding of this work is the novel protective mechanism of amifostine preconditioning against HTV-induced lung oxidative stress and associated barrier dysfunction via induction of SOD expression and SOD/catalase activity.
Several factors contribute to stretchinduced ROS generation in lung cells, including increased NADPH oxidase activity, and mitochondrial malfunction that leads to uncontrolled superoxide production, which may cause severe cellular oxidative stress (11, 14, 39, 42, 43) . HTV-induced lung dysfunction in this study was accompanied by lung tissue oxidative stress manifested by an increase in the protein nitrotyrosinylation and oxidation levels and elevated MDA levels in the lung tissue homogenates. In vitro experiments showed stretch-induced ROS production as early as 30 mins after exposure to lung epithelial and ECs (11, 14) , suggesting direct ROS involvement in the pathogenesis of VILI.
Our data show HTV-induced the activation of the MAP kinases p38, Erk-1/2, JNK, NF-B cascade and activation of Rho-dependent myosin light chain phosphorylation that were linked to increased lung vascular endothelial permeability (44 -46) . In agreement with redoxdependent activation of stress-induced MAP kinase and NF-B signaling, these pathways were markedly suppressed by amifostine preconditioning and strongly correlated with attenuation of HTVinduced lung injury. The results also demonstrate that HTV-induced Erk 1/2 activation was not suppressed by amifostine. Because amifostine only partially attenuated barrier dysfunction, it is possible that Erk 1/2 may be involved in other mechanisms contributing to barrier dysfunction. A protective effect of amifostine on stress kinase and Rho pathways involved in lung barrier dysfunction was also observed in the cell culture two-hit model of VILI.
Amifostine is rapidly cleared from the bloodstream, as evidenced by a ten-fold decrease in concentration within 30 mins of injection in mice (47) . In this study the last amifostine injection was 24 hrs before HTV experiments, indicating the likelihood that amifostine had been cleared from the circulation well before the onset of experiments. Thus, the observed protective effects were attributed to a delayed, rather than immediate, amifostine action.
Our previous study (26) described the protective effects of amifostine treatment concurrent with intratracheal lipopolysaccharide instillation in an animal model of lipopolysaccharide-induced lung injury. Amifostine is effective in scavenging highly reactive free radicals by its active free thiol groups, and the mechanism underlying the protective effect of amifostine in that model was attributable to its capacity to scavenge excessive reactive free radicals generated in response to lipopolysaccharide stimulation. A number of reports, however, indicate that amifostine may increase cell resistance to radiation-induced death by a delayed mechanism via induction of SOD2 gene expression and enzymatic activity (48 -50) . The same mechanism may cause the observed amifostine-induced lung protection in VILI, because our data show increased expression of SOD in the lung samples and pulmonary EC cultures after 3 days of preconditioning with ami-fostine. This effect was not observed at earlier times (2 hrs) of amifostine pretreatment (data not shown).
It is important to note that in contrast to the reported protective effects of acute amifostine treatment in the model of lipopolysaccharide-induced lung injury, in which the maximal amifostine protective effect was observed at 200 mg/kg (26) , maximal protection by chronic pretreatment performed in this study was observed at a significantly lower dose (25 mg/kg). A key role of SOD2 in the amifostine-induced protective effects observed in the VILI model also was demonstrated in these experiments with the introduction of the SOD2 pharmacologic inhibitor DECT.
Inducible SOD2 expression is regulated by two transcription factors, NF-B (51) and the Forkhead Box O3a transcription factor (52) . Activation of the SOD2 gene expression also can be induced by thiol reducing agents, such as amifostine, and has been described as the thiolinduced SOD2-mediated "delayed radioprotective effect" (49, 53) . Amifostinetriggered cellular activation of NF-B leads to elevated SOD2 gene expression and a 10-to 20-fold build-up of active SOD2 enzyme, which peaks approximately 24 to 30 hrs later (49, 50) . The proposed mechanism of such NF-B activation is via reduction of cysteine residues on the p50 and p65 subunits of NF-B that results in its activation and enhanced binding to the NF-B binding sites of the SOD2 gene (54) . This in turn induces SOD2 gene expression and translocation of active SOD2 enzyme to the mitochondria.
Activation of NF-B by amifostine results in selective rather than global changes in the expression of genes containing NF-B-responsive elements (55) . This observation and the transient nature of NF-B activation may explain the apparent discrepancy between NF-Bdependent activation of SOD2 and inhibition of VILI-induced NF-B activation in amifostine-preconditioned lungs, which is attributable to SOD2-mediated reduction of oxidative stress and redoxdependent NF-B and stress kinase signaling.
Previous studies show that amifostine at a dose of 50 mg/kg was also more effective than a dose of 200 mg/kg in inhibiting metastases formation (56) and was more effective in inducing the conversion of plasminogen to angiostatin. Such bell-shaped dose responses are ex- Figure 8 . Amifostine pretreatment increases superoxide dismutase (SOD) activity in human pulmonary endothelial cells. Human pulmonary artery endothelial cells were pretreated with vehicle (phosphatebuffered saline) or amifostine for 3 days followed by 18% cyclic stretch with or without thrombin challenge. Control cells were left under static conditions. Measurements of SOD activity were performed in control and stimulated cells. Data are presented as mean Ϯ SD; n ϭ 3 for each group; *p Ͻ .05; ***p Ͻ .001. pected in the case of a reduction/oxidation (redox)-driven reaction, where each sulfohydryl moiety is considered as a reducing equivalent. Thus, at certain con-centrations, redox states reach a plateau level, and further increases may cause adverse reactions. For example, amifostine triggers hypoxic signaling (57) , which at high doses may impair its beneficial effects in the VILI model. Amifostine treatment also downregulated vascular endothelial growth factor receptor-2 expression in ECs and suppressed their ability to respond to exogenous vascular endothelial growth factor-A (58) . Vascular endothelial growth factor signaling plays a complex role in the pathogenesis of ALI. At high concentrations, vascular endothelial growth factor promotes vascular dysfunction, whereas basal levels are essential for endothelial and alveolar epithelial cell survival (59, 60) . Thus, imbalances between the beneficial activation of antioxidant defenses shown in the present study and desensitization of vascular endothelial growth factor signaling contributing to the development of ALI may be potential explanations of the decreased amifostine efficacy at higher concentrations.
Consistent with previous reports (27), chronic amifostine treatment did not upregulate catalase protein expression or enzymatic activity in the lung tissues or cultured pulmonary ECs. However, amifostine pretreatment prevented a decrease in catalase activity observed in the lungs of animals ventilated at HTV. The mechanism of this inhibitory effect is not entirely clear. Because catalase transcriptional activation is not regulated by amifostine, the most plausible explanation of preserved catalase activity in the lungs of HTV-exposed amifostine-preconditioned mice is attributable to the prevention of oxidative stress-induced posttranslational modifications that may lead to catalase inactivation. Figure 10 summarizes the major findings of this study and proposes a mechanism explaining the delayed amifostine protective effects in ventilator induced lung injury. Chronic treatment with amifostine causes induction of SOD2 protein expression and enzymatic activation of SOD2 and catalase, which in turn suppress HTV-induced ROS and reactive nitrogen species production, mitigate oxidative stress, and inhibit redoxsensitive stress signaling involved in inflammatory gene expression and barrier disruptive mechanisms in the lung.
VILI is a multifacet pathologic condition involving multiple pathologic mechanisms. Excessive CS of the lung associated with VILI may directly disrupt the plasma membrane (61, 62) and cause release and de novo production of inflammatory cytokines (interleukin-8, tumor necrosis factor-␣) and coagulation factors (tissue factor, thrombin), leading to vascular hyperpermeability and lung dys- . Amifostine (Amif) pretreatment attenuates cyclic stretch (CS)-induced and thrombininduced activation of stress cascades and barrier disruptive signaling. Human pulmonary artery endothelial cells were preconditioned with vehicle (phosphate-buffered saline) or amifostine followed by 18% CS with or without thrombin treatment or left static. A, Effect of amifostine preconditioning on activation of oxidative stress sensitive pathways was analyzed by Western blot with specific antibodies and quantitative densitometry analysis. Results of densitometry shown as mean Ϯ SD; n ϭ 4 for each group; *p Ͻ .05. B, Superoxide dismutase (SOD2) expression levels in human pulmonary artery endothelial cells were quantified by densitometry and normalized to ␤-tubulin. Results shown as mean Ϯ SD; n ϭ 6 for each group; *p Ͻ .05. function (62) (63) (64) . In addition, VILIassociated activation of surface adhesive molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule) (65-67) triggers neutrophil adhesion and infiltration into the lungs. Excessive mechanical stretch associated with VILI induces signal transduction triggered by myosin light chain kinase-dependent and RhoGTPase-dependent mechanisms and leads to EC cytoskeletal remodeling and permeability (35, 38) . Various strategies to reduce myosin light chain kinase or Rho signaling show promising results in the in vitro and in vivo models of VILI (6, 29, 30, 38, 68) . In addition to the myosin light chain kinase-dependent and Rhodependent mechanisms of lung barrier dysfunction, this study and other reports describe direct activation of ROS production and oxidative stress in VILI or pathologic CS in vitro (39, 42, 69) . Such oxidative stress activates cellular stress signaling and has been implicated in disruption of cell junction integrity, activation of cytoskeletal contractile machinery, and produc-tion of inflammatory mediators, which further exacerbate lung dysfunction. The results of this study and published data (39) suggest that the reduction of oxidative stress may be a promising strategy to suppress pathologic signaling in VILI. Thus, simultaneous targeting of several pathogenic mechanisms including oxidative stress (by amifostine), thrombin-induced procoagulant activities, and increased vascular permeability (by treatment with activated protein C), downregulation of mechanical stress-induced and agonistinduced Rho signaling via elevation of intracellular cAMP (68), regulation of microtubule dynamics (30) , or stimulation of Rac/Cdc42 signaling (70, 71 ) may prove to be efficient strategies to prevent or cure this devastating pathologic condition.
CONCLUSIONS
The results of this study strongly suggest that chronic amifostine treatment may reduce pathologic ROS production in the clinical setting associated with ALI and may be considered as a preventive treatment for a wider spectrum of ALI syndromes associated with pathologic elevation of ROS production and oxidative stress. Although rigorous testing of various protocols of amifostine administration are still required, our results suggest that amifostine-mediated induction of cellular antioxidant defense mechanisms also may be beneficial at advanced ALI stages and improve resolution of ALI/ VILI. These are important directions for future studies. Figure 10 . Attenuation of ventilator-induced lung injury by amifostine. Mechanical stretch associated with high tidal volume (HTV) mechanical ventilation induces reactive oxygen species (ROS) and reactive nitrogen species (RNS) production, leading to activation of redox-sensitive stress kinases (JNK and p38 MAPK) and nuclear factor-B signaling cascade leading to expression of proinflammatory cytokines, cytoskeletal remodeling, and disruption of endothelial monolayer integrity. Amifostine attenuates oxidative stress induced by HTV through upregulation of superoxide dismutase (SOD) protein expression and stimulation of SOD and catalase enzymatic activities. CS, cyclic stretch; XOR, xanthine oxidoreductase; MAPKAPK2, MAPK-activated protein kinase 2; Hsp27, heat shock protein 27; MLC, myosin light chains; ROCK, Rho-associated kinase; MYPT, myosin protein phosphatase.
